Takeda, CSL Behring fold big plasma alliance after PhIII flop — joining a slew of antibodies that failed to help hospitalized patients

The big plasma alliance spearheaded by Takeda and CSL Behring has a big Phase III verdict: Adding their hyperimmune intravenous immunoglobulin product to Gilead’s remdesivir does not stall disease progression.

Dubbed H-Ig, the treatment was supposed to be a higher grade version of convalescent plasma, which former President Donald Trump...

Click to view original post